George Health is the commercial arm of The George Institute for Global Health and a profit-for-purpose company focused on late-stage development and commercialization of affordable medicines and health technologies. Its businesses include George Clinical, Ellen Medical Devices, George Health Technologies and George Medicines, which targets cardiometabolic conditions. Product efforts cited include a near‑registration medicine to prevent recurrent heart attacks, a late‑stage antihypertensive, an innovative Type 2 diabetes treatment, a low‑cost digital clinical decision tool for multimorbidity, and an ultra‑low‑cost dialysis system. George Medicines develops fixed‑dose combinations of established drugs to improve efficacy, safety and affordability. The company was formed in 2014 and leverages exclusive commercial rights to The George Institute’s intellectual property and scientific expertise. The announcement highlights a $35 million financing to accelerate commercialization and scale-up of these programs.

Total raised

$35M

Funding rounds

1

Latest round

Equity

Latest activity

Mar 2020